CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates

Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipel

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the a

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected begi

PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company

Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-sta

PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company

Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lo

Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLD

Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian canc

29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian canc

PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up,

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the ana

Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim

Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-st

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC

Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) has been given a consensus recommendation

Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get

Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintai

Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight a

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the a

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a inte

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Compan

Context Therapeutics (NASDAQ: CNTX) CEO Martin Lehr outlined the company's strategy and upcoming cli

Shares of Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) have been assigned an average r

PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company

Context Therapeutics (NASDAQ: CNTX - Get Free Report) and Carisma Therapeutics (NASDAQ: CARM - Get F

Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Rep

  On Thursday, 498 companies reached new 52-week lows.

  On Wednesday, 345 companies set new 52-week lows.

  On Thursday, 175 stocks hit new 52-week lows.

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, i

  On Friday, 127 companies set new 52-week lows.